Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 71288-118

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 71288-118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Bor02 0002 01 V2)

FDA Label Image

Figure 1 (Bor02 0002 02 V2)

FDA Label Image

Figure 2 (Bor02 0002 03 V2)

FDA Label Image

Figure 3 (Bor02 0002 04 V2)

FDA Label Image

Figure 4 (Bor02 0002 05 V2)

FDA Label Image

Figure 5 (Bor02 0002 06 V2)

FDA Label Image

Figure 6 (Bor02 0002 07 V2)

FDA Label Image

Principal Display Panel – Bortezomib For Injection 3.5 mg Vial Label (Bor02 0002 08 V3)

FDA Label Image

Principal Display Panel – Bortezomib For Injection 3.5 mg Carton (Bor02 0002 09 V3)

This appears to be a package insert for the drug Bortezomib, which is a cytotoxic agent used for intravenous or subcutaneous injection only. The package includes one single-dose vial containing a lyophilized powder with 35mg of bortezomib and 35mg of mannitol. It provides instructions for reconstitution of the drug using either 0.9% Sodium Chloride or 0% Sodium Chioride, to achieve a final concentration of either 2.5mg per mL or 1mg per mL. The insert also includes NDC codes, storage information, and precautions.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.